¼¼Æ÷µ¶¼º ¾à¹° ¹× HPAPI Á¦Á¶ ½ÃÀå : Á¦Ç° À¯Çüº°, ±â¾÷ ±Ô¸ðº°, »ç¾÷ ±Ô¸ðº°, ºÐÀÚ À¯Çüº°, °íȰ¼º ¿Ï¼ºÁ¦Çü À¯Çüº°, ÁÖ¿ä Áö¿ªº° - ¾÷°è µ¿Çâ°ú ¼¼°è ¿¹Ãø(- 2035³â)
Cytotoxic Drugs & HPAPI Manufacturing Market by Type of Product, Company Size, Scale of Operation, Type of Molecule, Type of Highly Potent Finished Dosage Form, and Key Geographies: Industry Trends and Global Forecasts, Till 2035
»óǰÄÚµå : 1682710
¸®¼­Ä¡»ç : Roots Analysis
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 338 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,799 £Ü 6,943,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,999 £Ü 10,126,000
PDF (One-Location Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ Æ¯Á¤ »ç¾÷ ºÎ¹®¿¡ ¼ÓÇÑ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,599 £Ü 15,335,000
PDF (Department License) help
PDF º¸°í¼­¸¦ ºÎ¼­ ´ÜÀ§·Î 12¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,999 £Ü 26,042,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°è ¼¼Æ÷µ¶¼º ¾à¹° ¹× HPAPI Á¦Á¶ ½ÃÀå ±Ô¸ð´Â 2035³â±îÁö ¿¹Ãø ±â°£ µ¿¾È 11.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î È®´ëµÇ¾î ÇöÀç 117¾ï ´Þ·¯¿¡¼­ 2035³â±îÁö 399¾ï ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÓ»ó¾à¸®ÇÐ ¹× Á¾¾çÇÐ ¿¬±¸ÀÇ ¹ßÀü°ú Ç¥ÀûÄ¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ °í¾à¸®È°¼º ¼ººÐ(HPAPI)°ú ¼¼Æ÷µ¶¼º ¾à¹°Àº Àü ¼¼°è ¿¬±¸ÀÚµé°ú Á¦¾àȸ»çµéÀÇ Áß¿äÇÑ °ü½É»ç°¡ µÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀǾàǰÀÇ 45%°¡ °í¾à¹° Ȱ¼º ¼ººÐÀ̶ó´Â »ç½ÇÀº ÁÖ¸ñÇÒ ¸¸ÇÕ´Ï´Ù. ±×·¯³ª HPAPIÀÇ Á¦Á¶´Â º¹ÀâÇÑ °úÁ¤À̱⠶§¹®¿¡ ±× °úÁ¤¿¡´Â ¿©·¯ °¡Áö ¹®Á¦°¡ ÀÖ½À´Ï´Ù. °¡Àå Å« °úÁ¦´Â Á¦Á¶ °úÁ¤¿¡¼­ ±³Â÷ ¿À¿°À» ¹æÁöÇÏ´Â °ÍÀ̸ç, ±× ´ÙÀ½À¸·Î´Â ȯ°æ, ±Ù·ÎÀÚ ¹× Àüü °ø±Þ¸Á¿¡ °ÉÄ£ ¸ðµç »ç¶÷À» º¸È£ÇÏ´Â °ÍÀÔ´Ï´Ù. °Ý¸® Àåºñ, ÀýÂ÷, PPE µî ¿Ã¹Ù¸¥ °Ý¸® ¹× º¸È£ Àü·«À» ¼±ÅÃÇÏ´Â °Íµµ ¸¶Âù°¡Áö·Î Áß¿äÇϸç, HPAPI Ãë±ÞÀº ÀϹÝÀûÀ¸·Î ¾ÈÀüÇÑ Ãë±Þ ¿µ¿ª¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ°¡ ÇÊ¿äÇϸç, ¼¼°è Áöħ°ú °íµµÀÇ ±â¼ú Àü¹® Áö½ÄÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ ÀÌ ¿µ¿ªÀÇ µµÀü¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ßÀÇ µµÀü¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Á¦¾àȸ»çµéÀº Àû±ØÀûÀ¸·Î Á¦Á¶ ¾÷¹«¸¦ ¾Æ¿ô¼Ò½ÌÇϰí ÀÖ½À´Ï´Ù.

À§Å¹»ý»ê ½ÃÀåÀÇ Å« ÀáÀç·Â°ú ±àÁ¤ÀûÀÎ ¼ºÀå Àü¸ÁÀ» ÀÌÇØÇϰí ÀÖ´Â ´ëºÎºÐÀÇ ´ëÇü Á¦¾à»çµéÀº ÇöÀç Á¦Á¶ ½Ã¼³À» È®Àå ¹× ¾÷±×·¹À̵åÇϱâ À§ÇÑ ÅõÀÚ¸¦ °í·ÁÇϰí ÀÖ½À´Ï´Ù. ¸¹Àº CMOµéÀÌ ÀϺ», Áß±¹, Àεµ, ºê¶óÁú µî ½ÅÈï±¹ÀÇ ³·Àº Á¦Á¶ ºñ¿ë, Àú·ÅÇÑ ÀΰǺñ, ¼÷·ÃµÈ ³ëµ¿·Â, ±ÔÁ¦ ȯ°æ µîÀÇ ÀÌÁ¡À» ´©¸®±â À§ÇØ »õ·Î¿î ½Ã¼³¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. Ç×¾ÏÁ¦ »ê¾÷ Àü¹ÝÀÇ ¼ºÀå, ÃÖ±Ù ±â¼ú ¹ßÀü, ¾Æ¿ô¼Ò½Ì Áõ°¡ Ãß¼¼¿¡ ÈûÀÔ¾î ÇâÈÄ 10³â°£ ½ÃÀåÀº ¾ÈÁ¤ÀûÀÎ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÇöÀç 140°³ ÀÌ»óÀÇ ±â¾÷ÀÌ ´Ù¾çÇÑ ±Ô¸ðÀÇ °íȰ¼º È­ÇÕ¹° ¼öŹ Á¦Á¶ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â µ¥ ÇÊ¿äÇÑ Àü¹® Áö½ÄÀ» º¸À¯Çϰí ÀÖ´Ù°í ÁÖÀåÇϰí ÀÖ½À´Ï´Ù. ÇöÀç ½ÃÀå »óȲÀº ¸Å¿ì ¼¼ºÐÈ­µÇ¾î ÀÖÀ¸¸ç, ÁÖ¿ä Áö¿ª¿¡ °ÉÃÄ ½Å±Ô ÁøÃâ±â¾÷°ú ±âÁ¸ ±â¾÷ÀÌ ¸ðµÎ Á¸ÀçÇÕ´Ï´Ù. ÀÌÇØ°ü°èÀÚµéÀº Àü¹® Áö½ÄÀ» Ȱ¿ëÇÏ¿© ¼ö¸¹Àº °íȰ¼º È­ÇÕ¹°ÀÇ ¼öŹ Á¦Á¶ ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ¾à 70%ÀÇ ¼­ºñ½º Á¦°ø¾÷ü°¡ HPAPI ºÐ¼® Å×½ºÆ® ¿ª·®À» º¸À¯Çϰí ÀÖ½À´Ï´Ù. ÀÌ ºÐ¾ß¿¡ ´ëÇÑ °ü½ÉÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº Á¦ÈÞ È°µ¿ÀÇ È°¼ºÈ­¿¡¼­ ¾Ë ¼ö ÀÖ½À´Ï´Ù. ½ÇÁ¦·Î HPAPI¿Í ¼¼Æ÷µ¶¼º ¾à¹° Á¦Á¶¿Í °ü·ÃµÈ Á¦ÈÞ°¡ ÃÖ±Ù °¡Àå ¸¹ÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. °íȰ¼º È­ÇÕ¹°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ CMOµéÀº ½Ã¼³°ú ¿ª·®À» È®´ëÇϱâ À§ÇÑ ÅõÀÚ¸¦ ¾Æ³¢Áö ¾Ê°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¹Ì±¹, ½ºÀ§½º, ¿µ±¹¿¡¼­ µÎµå·¯Áö°Ô ³ªÅ¸³ª°í ÀÖ½À´Ï´Ù.

Cytotoxic Drugs &HPAPI Manufacturing Market-IMG1

HPAPIÀÇ ¼¼°è À§Å¹»ý»ê ´É·ÂÀº ´Ù¾çÇÑ Áö¿ª¿¡ ºÐ»êµÇ¾î ÀÖÀ¸¸ç, ÇöÀç ´É·ÂÀÇ 80%´Â ÃÊ´ëÇü ±â¾÷ÀÌ ¼ÒÀ¯ÇÑ ½Ã¼³¿¡ ¼³Ä¡µÇ¾î ÀÖ½À´Ï´Ù. Ç×ü ÀǾàǰ Á¢ÇÕü´Â °íȰ¼º È­ÇÕ¹°ÀÇ °¡Àå Àαâ Àִ Ŭ·¡½º Áß ÇϳªÀ̸ç, ÇöÀç 30°³ ÀÌ»óÀÇ ±â¾÷ÀÌ ÀÌ·¯ÇÑ ¹ÙÀÌ¿À ÀǾàǰÀÇ ¼öŹ Á¦Á¶ ¹× Á¢ÇÕ ¼­ºñ½º¸¦ Á¦°øÇÑ´Ù°í ÁÖÀåÇϰí ÀÖ½À´Ï´Ù. °íȰ¼º ÀǾàǰ °³¹ß ±â¾÷µéÀº Á¦Á¶ ¾÷¹«¸¦ ¾Æ¿ô¼Ò½ÌÇÒ °¡´É¼ºÀÌ ³ôÀ¸¸ç, ¼­ºñ½º ±â¹Ý ¼öÀÍÀº ¿¬°£ 11.6%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Cytotoxic Drugs &HPAPI Manufacturing Market-IMG2

¼¼°èÀÇ ¼¼Æ÷µ¶¼º ¾à¹° ¹× HPAPI Á¦Á¶ ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² Á¦Ç° À¯Çüº°/±â¾÷ ±Ô¸ðº°/»ç¾÷ ±Ô¸ðº°/ºÐÀÚ À¯Çüº°/°íȰ¼º ¿ÏÁ¦ÀǾàǰ À¯Çüº°/ÁÖ¿ä Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÃâ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼­·Ð

Á¦4Àå ½ÃÀå ±¸µµ

Á¦5Àå ±â¾÷ °æÀï·Â ºÐ¼®

Á¦6Àå ±â¾÷ °³¿ä : ºÏ¹ÌÀÇ ¼¼Æ÷µ¶¼º ¾à¹° ¹× HPAPI Á¦Á¶¾÷ü

Á¦7Àå ±â¾÷ °³¿ä : À¯·´ÀÇ ¼¼Æ÷µ¶¼º ¾à¹° ¹× HPAPI Á¦Á¶¾÷ü

Á¦8Àå ±â¾÷ °³¿ä : ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× ±âŸ Áö¿ªÀÇ ¼¼Æ÷µ¶¼º ¾à¹° ¹× HPAPI Á¦Á¶¾÷ü

Á¦9Àå ÆÄÆ®³Ê½Ê ¹× Çù¾÷

Á¦10Àå ÃÖ±Ù È®Àå

Á¦11Àå ¿ë·® ºÐ¼®

Á¦12Àå Áö¿ª ´É·Â Æò°¡ ºÐ¼®

Á¦13Àå Á¦Á¶ vs. ±¸ÀÔ ÀÇ»ç ÀÇ»ç°áÁ¤ ÇÁ·¹ÀÓ¿öÅ©

Á¦14Àå ½ÃÀå ±Ô¸ð Æò°¡¿Í ±âȸ ºÐ¼®

Á¦15Àå SWOT ºÐ¼®

Á¦16Àå »ç·Ê : Ç×ü ¾à¹° °áÇÕü ¼öŹÁ¦Á¶

Á¦17Àå °á·Ð

Á¦18Àå ÁÖ¿ä ÀλçÀÌÆ®

Á¦19Àå ºÎ·Ï 1 : Ç¥ Çü½Ä µ¥ÀÌÅÍ

Á¦20Àå ºÎ·Ï 2 : ±â¾÷ ¹× ´Üü ¸®½ºÆ®

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

CYTOTOXIC DRUGS AND HPAPI MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global cytotoxic drugs and HPAPI manufacturing market is estimated to grow from USD 11.7 billion in the current year to USD 39.9 billion by 2035, at a CAGR of 11.6% during the forecast period, till 2035.

The market opportunity for cell and gene therapy supply chain software has been distributed across the following segments:

Type of Product

Scale of Operation

Type of Molecule

Type of Highly Potent Finished Dosage Form

Key Geographical Regions

CYTOTOXIC DRUGS AND HPAPI MANUFACTURING MARKET: GROWTH AND TRENDS

With advances in clinical pharmacology and oncology research, and the increasing demand for targeted therapies, high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have become the key focus of researchers and drug manufacturers across the world. It is worth highlighting that 45% of the drugs globally are highly potent leading to specialized HPAPI production. However, manufacturing HPAPIs is a complex process and therefore, there are various challenges associated with the process. The biggest challenge is to inhibit cross-contamination during manufacturing followed by the protection of the environment, workers and everyone across the supply chain. It is equally important to choose the correct containment and protective strategy, inclusive of containment equipment, procedures and PPE. HPAPIs handling generally requires continued investment in the area of safe handling, the need for global guidance and advance technical expertise adding to the challenges in the domain. Therefore, drug developers are actively outsourcing their manufacturing operations.

Understanding the vast potential and positive growth outlook of the contract manufacturing market, the majority of big pharma players are looking to make investments to expand and / or upgrade their current manufacturing facilities. A number of CMOs are investing in new facilities in developing countries such as Japan, China, India and Brazil to avail the benefits of lower manufacturing costs, cheap and skilled labor and supportive regulatory landscapes in these areas. Driven by the overall growth of the anti-cancer therapeutics industry, recent technological advancements and the growing trend of outsourcing, the market is anticipated to witness steady growth in the coming decade.

CYTOTOXIC DRUGS AND HPAPI MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the cytotoxic drugs & HPAPI manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Cytotoxic Drugs & HPAPI Manufacturing Market - IMG1
Cytotoxic Drugs & HPAPI Manufacturing Market - IMG2

CYTOTOXIC DRUGS & HPAPI MANUFACTURING MARKET: KEY SEGMENTS

HPAPI Segment Occupies the Largest Share of the Cytotoxic Drugs and HPAPI Manufacturing Market

Based on the type of product, the market is segmented into HPAPI and highly potent finished dosage forms. At present, HPAPI segment holds the maximum share of the cytotoxic drugs & HPAPI manufacturing market. This trend is unlikely to change in the near future.

Very Large Players are Likely to Dominate the Cytotoxic Drugs & HPAPI Manufacturing Market During the Forecast Period

Based on the company size, the market is segmented into small, mid-sized, large and very large companies. At present, very large companies hold the maximum share of the cytotoxic drugs & HPAPI manufacturing market. This trend is likely to remain the same in the coming decade.

By Scale of Operation, Commercial Scale is Likely to Dominate the Cytotoxic Drugs and HPAPI Manufacturing Market

Based on scales of operation, the market is segmented into preclinical, clinical and commercial scale. It is worth highlighting that, at present, commercial scale holds a larger share of the cytotoxic drugs and HPAPI manufacturing market. This trend is likely to remain the same in the forthcoming years.

Biologics is the Fastest Growing Segment of the Cytotoxic Drugs and HPAPI Manufacturing Market During the Forecast Period

Based on the type of molecule, the market is segmented into small molecules and biologics. It is worth highlighting that, at present, small molecules dominate the cytotoxic drugs and HPAPI manufacturing market. This is primarily due to the fact the CMOs have invested and expanded their capabilities for highly potent small molecules. It is important to note the demand for highly potent drugs is on the rise therefore the market for biologics is expected to grow at a faster pace in the coming decade.

Oral FDFs are Likely to Dominate the Cytotoxic Drugs and HPAPI Manufacturing Market During the Forecast Period

Based on the type of highly potent finished dosage forms, the market is segmented into injectables, oral solids, creams and other FDFs. It is worth highlighting that, at present, oral FDFs capture the highest share of the cytotoxic drugs and HPAPI manufacturing market. This trend is likely to remain the same in the coming decade owing to the benefits offered by oral formulations, such as cost-efficiency for manufacturers, comfort and ease of use for patients.

Europe Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. The majority of the share is expected to be captured by players based in Europe. This is due to the fact that there are well-established players in this region with considerable installed capacities and capabilities. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Cytotoxic Drugs & HPAPI Manufacturing Market

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

CYTOTOXIC DRUGS AND HPAPI MANUFACTURING MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE

5. COMPANY COMPETITIVENESS ANALYSIS

6. COMPANY PROFILES: HPAPI AND CYTOTOXIC DRUG MANUFACTURERS IN NORTH AMERICA

7. COMPANY PROFILES: HPAPI AND CYTOTOXIC DRUG MANUFACTURERS IN EUROPE

8. COMPANY PROFILES: HPAPI AND CYTOTOXIC DRUG MANUFACTURERS IN ASIA-PACIFIC AND REST OF THE WORLD

9. PARTNERSHIPS AND COLLABORATIONS

10. RECENT EXPANSIONS

11. CAPACITY ANALYSIS

12. REGIONAL CAPABILITY ASSESSMENT ANALYSIS

13. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

14. MARKET SIZING AND OPPORTUNITY ANALYSIS

15. SWOT ANALYSIS

16. CASE-IN-POINT: CONTRACT MANUFACTURING OF ANTIBODY DRUG CONJUGATES

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â